title: Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis.
abstract: OBJECTIVE
  We evaluated the effectiveness and safety of adalimumab in a large cohort of patients with active ankylosing spondylitis (AS) and identified clinical predictors of good clinical response.
  
  
  METHODS
  Patients with active AS [Bath AS Disease Activity Index (BASDAI)>or=4] received adalimumab 40 mg every other week in addition to their standard antirheumatic therapies in a multinational 12-week, open-label study. We used 3 definitions of good clinical response: 50% improvement in the BASDAI (BASDAI=50), 40% improvement in the ASsessments of SpondyloArthritis International Society criteria (ASAS40), or ASAS partial remission. Response predictors were determined by logistic regression with backward elimination (selection level 5%).
  
  
  RESULTS
  Of 1250 patients, 1159 (92.7%) completed 12 weeks of adalimumab treatment. At Week 12, 57.2% of patients achieved BASDAI 50, 53.7% achieved ASAS40, and 27.7% achieved ASAS partial remission. Important predictors of good clinical response (BASDAI 50, ASAS40, and partial remission) were younger age (p<0.001), and greater C-reactive protein (CRP) concentration (p<or=0.001), HLA-B27 positivity (p<or=0.01), and tumor necrosis factor (TNF) antagonist naivety (p<0.001).
  
  
  CONCLUSIONS
  Adalimumab was effective in this large cohort of patients with AS, with more than half of patients achieving a BASDAI 50 or ASAS40 response and more than a quarter of patients reaching partial remission at Week 12.Younger age, greater CRP concentrations, HLA-B27 positivity, and TNF antagonist naivety were strongly associated with BASDAI 50, ASAS40, and partial remission responses. ClinicalTrials.gov identifier: NCT00478660.
authors.affiliation: Charité-University Medicine Berlin, Campus Benjamin Franklin Hospital, Medical Department I, Rheumatology, Hindenburgdamm 30, 12200 Berlin, Germany. martin.rudwaleit@charite.de
authors.forename: Martin
authors.initials: M
authors.lastname: Rudwaleit
authors.forename: Pascal
authors.initials: P
authors.lastname: Claudepierre
authors.forename: Paul
authors.initials: P
authors.lastname: Wordsworth
authors.forename: Eduardo Loza
authors.initials: EL
authors.lastname: Cortina
authors.forename: Joachim
authors.initials: J
authors.lastname: Sieper
authors.forename: Martina
authors.initials: M
authors.lastname: Kron
authors.forename: Roberto
authors.initials: R
authors.lastname: Carcereri-De-Prati
authors.forename: Hartmut
authors.initials: H
authors.lastname: Kupper
authors.forename: Sonja
authors.initials: S
authors.lastname: Kary
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D011446:Prospective Studies; D012074:Remission Induction; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000068879:Adalimumab